Ozempic and Alcohol Cravings: What the Science Says

Somewhere in the last two years, the same odd report started showing up in medical journals and on Reddit at roughly the same time. People who went on Ozempic for weight or diabetes kept noticing something nobody had prescribed it for: they'd stopped wanting to drink. That's a strange thing about a diabetes drug. So let's take it apart. What GLP-1 actually is, why it might touch alcohol at all, what the research shows, and the part it can't fix.

What GLP-1 is

GLP-1 is a hormone your gut already makes. Every time you eat, it rises, travels to the brain, and delivers a simple message: that's enough, you can stop now.

Semaglutide, the drug sold as Ozempic and Wegovy, is a copy of that hormone that lasts far longer than the version your body produces. It was built to treat type 2 diabetes, approved for that in 2017, then approved for obesity in 2021.

The drinking part was an accident. People started taking these medications in large numbers, and a portion of them mentioned that their relationship with alcohol had changed.

Why a weight drug would touch drinking

GLP-1 receptors aren't only in your gut. They sit in the brain's reward system too, in the same regions alcohol acts on. When you drink, dopamine rises in a structure called the nucleus accumbens, and that surge is a big part of what makes the next drink feel necessary. In animal studies, GLP-1 medication tempers that surge.

The same circuitry that decides whether you reach for a second bite has a hand in whether you reach for a second glass.

Ziyad Al-Aly, a clinical epidemiologist who has studied these drugs at scale, has made the point well: the reason GLP-1 medication seems to work across alcohol, nicotine and opioids isn't that it targets any one of them. It seems to act on craving itself, the pull toward whatever a person is reaching for.

What the research shows

In 2025, a randomized trial published in JAMA Psychiatry gave low-dose semaglutide to adults with alcohol use disorder. They drank less in a controlled setting and reported less craving than the group on placebo. It was small and short, and the authors said plainly what good scientists say: the result justifies a larger trial; it doesn't settle anything.

In 2026, a trial in Copenhagen found that adding weekly semaglutide to therapy further reduced heavy drinking days in patients who also had obesity. And a Swedish study of more than 200,000 people with alcohol use disorder found that those also taking a GLP-1 medication were less likely to end up hospitalized for their drinking.

That last one is association, not proof; people on these drugs differ from people who aren't in ways a study can't fully strip out. But put the three together and the arrow keeps pointing the same way.

What it can't do

GLP-1 medication is not approved for alcohol use disorder. Using it for that today is off-label Most of the strongest data so far comes from people who also have obesity, so we don't yet know how well it works for someone whose only issue is drinking. And there's a catch the early reports keep mentioning: when people stop the medication, the cravings tend to come back. It manages something; it doesn't appear to cure it.

Then there's the part no drug touches. If you were drinking to get through grief, or anxiety, or a marriage you can't talk about, a medication that lowers craving doesn't answer any of that. It removes the thing you were using to avoid the question.

The willpower story is finally falling apart

Fewer than one in ten people with alcohol use disorder ever get any treatment, and only around 1.6 percent are offered a medication for it. We've had medications that help for decades. Most people who could use them have never been told they exist.

For about a century we've treated drinking as a test of character, and we built our whole response around that belief. If willpower is the cure, then medication looks like cheating.

But the willpower story was never accurate. Drinking that has tipped into a disorder is a condition with real biology, much of it happening in circuits you don't get a vote in.

No two people drink for the same reasons, and no single medication fits all of them. One person does well on something that lowers craving. Another does better on a drug that takes the reward out of the drink itself, the approach behind the Sinclair Method and naltrexone. A longer menu is how treatment finally starts fitting the person, instead of handing everyone the same instruction to try harder.

The most promising development in alcohol treatment in a generation arrived by accident, inside a drug designed for something else entirely. That tells you how little attention this field has had.

None of this means a prescription is the answer for you. It means the question was never whether you wanted to stop badly enough.

Stay Sober // Stay Cool

Monica

High Sobriety Club

Common questions about Ozempic and alcohol

Does Ozempic reduce alcohol cravings? For some people, yes. In early trials and a growing pile of personal reports, people taking semaglutide (Ozempic) drank less and craved less than expected. GLP-1 medication appears to act on the brain's reward system, the same circuitry alcohol uses. It isn't approved for this and the effect isn't universal, but the signal is consistent.

Why does Ozempic make you not want to drink? GLP-1 receptors sit in the brain regions that process reward and craving, not only in the gut. By tempering the dopamine response that makes a drink feel rewarding, the medication seems to reduce the pull toward alcohol. Researchers think it may act on craving itself rather than on alcohol specifically, which is why similar effects show up with nicotine and other substances.

Is GLP-1 approved to treat alcohol use disorder? No. As of 2026, GLP-1 medications like semaglutide are approved for type 2 diabetes and obesity, not for alcohol use disorder. Any use for drinking is off label and should only happen under medical supervision. Larger trials are underway.

What does the research say about semaglutide and alcohol? A 2025 JAMA Psychiatry trial found low dose semaglutide reduced drinking and craving in adults with alcohol use disorder. A 2026 Copenhagen trial and a large Swedish population study point the same way, especially in people who also have obesity. The evidence is early but consistent, and none of it is yet proof.

Do alcohol cravings come back if you stop taking it? Early reports suggest they often do. GLP-1 medication appears to manage cravings while you take it rather than permanently resetting them, which is one reason it isn't a standalone fix. The reasons behind the drinking still need their own attention.

Are there other medications for alcohol use disorder? Yes, and most people are never told about them. Naltrexone, used in the Sinclair Method, takes the reward out of drinking. Acamprosate and disulfiram work in other ways. Fewer than 2 percent of people with alcohol use disorder are currently offered any of them. If you're curious, it's a conversation to have with a doctor.

If your drinking has started to feel like something you manage rather than enjoy, you don't have to work it out alone, or wait until it gets worse. High Sobriety Club offers sober coaching in Munich and online, in English, German and Romanian. Book a free intro call.

Sources

• Hendershot et al., once-weekly semaglutide in adults with alcohol use disorder, JAMA Psychiatry, 2025

• NIH / NIAAA, semaglutide plus therapy reduces heavy drinking (Copenhagen trial), 2026

• Lähteenvuo et al., GLP-1 medications and alcohol use disorder outcomes, JAMA Psychiatry, 2024 (Swedish cohort, 227,868 people)

• Chuong et al. (Leggio lab), semaglutide and alcohol intake, JCI Insight, 2023

• Al-Aly et al., GLP-1 receptor agonists and substance use outcomes

• NIAAA, treatment gap and medication use in alcohol use disorder